JW (Cayman) Therapeutics Future Growth
Future criteria checks 2/6
JW (Cayman) Therapeutics's earnings are forecast to decline at 1.8% per annum while its annual revenue is expected to grow at 44.8% per year. EPS is expected to decline by 1.8% per annum.
Key information
-1.8%
Earnings growth rate
-1.8%
EPS growth rate
| Biotechs earnings growth | 37.6% |
| Revenue growth rate | 44.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 553 | N/A | -235 | N/A | 1 |
| 12/31/2025 | 319 | -609 | -516 | -568 | 1 |
| 12/31/2024 | 183 | -733 | -743 | -781 | 1 |
| 6/30/2024 | 173 | -628 | -369 | -349 | N/A |
| 3/31/2024 | 173 | -698 | -391 | -374 | N/A |
| 12/31/2023 | 174 | -768 | -413 | -398 | N/A |
| 9/30/2023 | 171 | -783 | -448 | -401 | N/A |
| 6/30/2023 | 167 | -797 | -483 | -404 | N/A |
| 3/31/2023 | 157 | -822 | -560 | -470 | N/A |
| 12/31/2022 | 146 | -846 | -637 | -537 | N/A |
| 9/30/2022 | 121 | -849 | -681 | -594 | N/A |
| 6/30/2022 | 97 | -851 | -724 | -651 | N/A |
| 3/31/2022 | 64 | -777 | -711 | -606 | N/A |
| 12/31/2021 | 31 | -702 | -698 | -561 | N/A |
| 9/30/2021 | 15 | -998 | -638 | -498 | N/A |
| 6/30/2021 | -1 | -1,294 | -577 | -435 | N/A |
| 3/31/2021 | 0 | -1,479 | -488 | -348 | N/A |
| 12/31/2020 | N/A | -1,664 | -398 | -261 | N/A |
| 9/30/2020 | 3 | -1,295 | -386 | -227 | N/A |
| 6/30/2020 | 6 | -925 | -374 | -192 | N/A |
| 3/31/2020 | 6 | -779 | -338 | -190 | N/A |
| 12/31/2019 | 5 | -633 | -303 | -189 | N/A |
| 12/31/2018 | 0 | -273 | -150 | -106 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JNY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: JNY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: JNY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: JNY's revenue (44.8% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: JNY's revenue (44.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if JNY's Return on Equity is forecast to be high in 3 years time